STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds

The US healthcare system has been in the spotlight this week, with a mix of concerning trends and positive developments. On one hand, a new analysis found that prescription drug shortages remain a "systemic" problem, despite a 23% drop in the number of shortages last year. On the other hand, the FDA approved a new sunscreen ingredient for the first time in over 25 years, and the Trump administration warned hospitals to increase price transparency or face fines.

What Happened

• The FDA approved a new sunscreen ingredient, avobenzone, for use in the US market.
• The Trump administration sent warnings to over 500 hospitals, requiring them to provide more price information to the public.
• The National Institutes of Health (NIH) appointed a new acting director for its infectious disease institute.
• A new analysis found that prescription drug shortages remain a significant problem in the US.
• Members of the Diabetes Association were expelled from an annual meeting for protesting NIH funding cuts.

Why It Matters

The ongoing shortage of prescription medications is a serious concern, as it can lead to delayed or foregone treatment for patients. The FDA's approval of a new sunscreen ingredient is a positive step towards improving public health, particularly in the prevention of skin cancer. The Trump administration's push for hospital price transparency is also a significant development, as it aims to increase accountability and reduce costs for patients.

What Experts Say

"The shortage of prescription medications is a complex issue that requires a multifaceted solution." — **John Powers III**, Acting Director of the National Institute of Allergy and Infectious Diseases (NIAID)

Key Numbers

• **23%: The decrease in prescription drug shortages in the US last year.

Background

The US healthcare system has been facing numerous challenges in recent years, including rising costs, access disparities, and funding cuts. The NIH has been a target of funding cuts, which has led to concerns about the impact on medical research and public health.

Key Facts

• What: Prescription drug shortages, NIH funding cuts, sunscreen ingredient approval, hospital price transparency
• When: This week

What Comes Next

As the US healthcare system continues to evolve, it is likely that we will see more developments on these fronts. The FDA's approval of new sunscreen ingredients may lead to increased innovation in the field, while the Trump administration's push for hospital price transparency may lead to greater accountability and cost reductions. The NIH's new leadership may also bring changes to the organization's priorities and funding allocations.